

CURRICULUM VITAE



NAME Margaret Kuan-Ju Sallbeg Chen

CONTACT INFORMATION

Swedish Institute for Infectious Disease Control, Nobels vag 18, 171 82 Solna, Sweden

TEL +46-8-457 2559. E-MAIL Margaret.Chen@ki.se

BORN Taipei Taiwan 1967

CIVIL STATUS Married

LANGUAGES

Swedish: Fluent, English: Fluent, Chinese: Fluent

Studied German and Spanish

CURRENT POSITION

Research Scientist/Microbiologist, Division of Vaccine Research, Department of Immunology and Vaccinology at The Swedish Institute for Infectious Disease Control

Associate Professor in Infection Biology at Karolinska Institutet, Sweden

ACADEMIC TRAINING

1992: Doctor of Dental Surgery (DDS), Karolinska Institutet

1998: PhD in Clinical Virology, Karolinska Institutet

1994-1996: Postdoc I: Department of Molecular Biology, The Scripps Research Institute, La Jolla, USA

1998-2000: Postdoc II: Microbiology and Tumor Biology Center, Karolinska Institutet.

2004: Associate Professor in Infection Biology at Karolinska Institutet

PREVIOUS EMPLOYMENTS

1992-1994: General Practitioner in Dentistry, Jönköping, Sweden

1994-1998: PhD student fellow, Karolinska Institutet

1995-1998: Postdoctoral Fellow at The Scripps Research Institute

1998-2000: Research Fellow at Karolinska Institutet

2003: Study Director of Postgraduate Studies at Department of Microbiology and Tumor Biology, Karolinska Institutet

INTERNATIONAL ASSIGNMENTS

Scientific consultant for the Vaccine Research Institute in San Diego, USA

COMMISSIONS OF TRUST

Reviewer for the American Journal of Pathology, Vaccine, Cancer Detection and Prevention, European Respiratory Journal, Scandinavian Journal of Immunology.

PUBLICATION LIST

1. Schulz O, Diebold SS, **Chen M**, Näslund T, Nolte M, Alexopoulou L, Azuma YT Flavell R, Liljeström P, and Reis e Sousa. 2005. Toll-like receptor 3 mediates dendritic cell activation by virus-infected cells and promotes cross-priming in vivo. *Nature*. 433:887.
2. **Chen M**, Barnfield C, Näslund T, Fleeton M, Liljeström P. 2005. MyD88 expression is required for efficient cross-presentation of virally infected cells. *J. Virol.* 79: 2964-2972.
3. **Chen M**, Sällberg M, Hughes J, Jones J, Guidotti L, Chisari F, Billaud JM, and Milich DR. 2005. Split immune tolerance between the hepatitis B virus precore and core proteins. *J. Virol.* 79 3016-3027.

4. **Chen M**, Billaud JM, Sällberg M, Guidotti L, Chisari F, Jones J, Hughes J and Milich DR. 2004. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. *Proc Natl Acad Sci U S A.* 12;101(41):14913-8
5. **Chen M**, Hu K-F, Rozell B, Örvell C, Morein B and Liljeström P. 2002. Vaccination with recombinant alphavirus or immune-stimulating complex against the respiratory syncytial virus. *J. Immunol.* 15;169(6):3208-16.
6. Brinster C, **Chen M**, Boucreux D, Paranhos-Baccala G, Liljeström P, Lemmonier, F and Inchauspé G. 2002. Cellular-mediated immune responses specific for hepatitis C virus non-structural protein 3 (NS3) following single or combined immunization with DNA- or Semliki-Forest virus particles. *J. Gen. Virol.* 83(Pt 2):369-81.
7. Colmenero P, **Chen M**, Castaños-Velez E, Liljeström P and M Jondal. 2002.. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. *Int. J. Cancer.* 98:554-560.
8. Hu KF, **Chen M**, Abusugra I, Monaco F, Morein B. 2001. Different respiratory syncytial virus and Quillaja saponin formulations induce murine peritoneal cells to express different proinflammatory cytokine profiles. *FEMS Immunol Med Microbiol.*31(2):105-12.
9. Fleeton M, **Chen M**, Berglund P, Murphy AM, Rhodes G, Parker SE, Atkins GJ and Liljeström P. 2001. Protection from viral infection upon vaccination with naked self-replicating RNA. *J. Inf. Dis.* 183:1395-8.
10. **Chen M**, Sällberg M, Thung SN, Hughes J, Jones J, Milich DR. 2001. Modeling the T-helper cell response in acute and chronic hepatitis B virus infection using T-cell receptor transgenic mice. *Antiviral Res.* 52(2):99-111.
11. Vidalin O, Fournillier A, Renard N, **Chen M**, Depla D, Boucreux D, Brinster C, Baumert T, Nakano T, Fukuda Y, Liljeström P, Trépo C and Inchauspé G. 2000. Use of conventional or replicating nucleic acid-based vaccines and recombinant semliki forest virus-derived particles for the induction of immune responses against hepatitis c virus core and e2 antigens. *Virology.* 25;276(2):259-70.
12. **Chen M**, Sällberg M, Jones J, Hughes J, Milich DR. 2000. Non-Deletional TCR-Transgenic Mice: A Model for the CD4+T Cell Repertoire in Chronic HBV Infection. *J. Virol.* 74(16):7587-99.
13. Lazdina U, Hultgren C, **Chen M**, Fischler B, Weiland O, Mushahwar IK, Sällberg M. 2000. Humoral and cellular immune responses to the GB virus C/hepatitis G virus envelope 2 protein. *J Med Virol.*62(3):334-44.
14. **Chen M**, Fischler B, Nemeth A, Sällberg M. 1999. Analysis of GB virus C markers in families over three generations. *J. Clin. Microbiol.* 37(12):4153-5.
15. Zhang Z-X, Peterson D, **Chen M**, Sällberg M. 1999. Pro- and eukaryotic expression of a single-chain antibody fragment that recognizes the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. *Clin. Diagn. Lab. Immunol.* 7(1):58-63.

16. **Chen M**, Sällberg M, Sönnernborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich D.R. 1999. Limited immunogenicity of the hepatitis C virus proteins. *Gastroenterology* 116(1):135-143.
17. **Chen M**, Sällberg M, Sönnernborg A, Jin L, Birkett A, Peterson D, Weiland O, Milich D.R. 1998. Human and murine antibody recognition is focused on the ATPase /helicase, but not the protease domain of the hepatitis C virus non-structural 3 protein. *Hepatology* 28(1):219-24.
18. Milich DR, **Chen M**, Hughes J, Jones J. 1998. The secreted hepatitis B e antigen preferentially depletes the Th1 cells via Fas-mediated mechanisms. *J. Immunol.* 15;160(4):2013-21.
19. Milich DR, **Chen M**, Schödel F, Peterson D, Jones J, Hughes J. 1997. Role of B cells in antigen presentation of the hepatitis B core. *Proc Natl Acad Sci U S A.* 94(26): 14648-14653.
20. Fischler B, Lara C, **Chen M**, Sönnernborg A, Nemeth A, Sällberg M. 1997. Genetic evidence for mother-to-infant transmission of hepatitis G (GB-C) virus. *J. Inf. Dis.* 176:281-285.
21. Sällberg M, Townsend K, **Chen M**, O´dea J, Banks T, Jolly D, Chang S, Lee WT, Milich DR. 1997. Characterization of humoral and CD4+ cellular responses after genetic immunization of the hepatitis B virus core and e antigens. *J. Virol.* 71:7:5295.
22. **Chen M**, Sönnernborg A, Johansson B, Sällberg M. 1997. Detection of hepatitis G (GB-C) virus in human saliva. *J. Clin. Microbiol.* 35:4:973-975.
23. Zhang Z-X, **Chen M**, Birkett A, Milich D.R, Sällberg M. 1996. Genotype specific immune response to the hepatitis C virus NS4a protein in immunized mice are homologous to those observed in HCV infected humans. *J. Gen. Virol.* 78:2735-2746.
24. Sällberg M, Zhang Z-X, **Chen M**, Jin L, Birkett A, Peterson D, Milich D.R. 1996. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. *J. Gen. Virol.* 77:2721-2728.
25. Weiland O, Chen M, Lindh G, Mattson L, Schwarcz R, Sönnernborg A, Wahl M, Wejstal R. 1995. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection. *Scan. J. Inf. Dis.* 27:319-324.
26. **Chen M**, Yun Z, Sällberg M, Schwarz R, Bergquist I, Berglund HB, Sönnernborg A. 1995. Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. *J. Med. Virol.* 43:223-226.
27. Zhang Z-X, Yun Z, **Chen M**, Sönnernborg A, Sällberg M. 1995. Evaluation of a multiple peptide assay for typing of antibodies to hepatitis C virus: Relation to genotyping by the polymerase chain reaction. *J. Med. Virol.* 45 (1):50-55.
28. **Chen M**, Sönnernborg A, Sällberg M. 1995. Levels of hepatitis C virus (HCV) RNA in serum and its relation to levels of immunoglobulin M and G antibodies against the HCV core protein. *J. Clin. Microbiol.* 33:778-780.

29. Zhang Z-X, **Chen M**, Sönnerborg A, Weiland O, Sällberg M. 1995. Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site directed serology of the HCV structural proteins. *J. Inf. Dis.* 171:1356-1359.
30. Zhang Z-X, **Chen M**, Sönnerborg A, Sällberg M. 1994. Antigenic structure of the nonstructural 2 and 5 protein of the hepatitis C virus: Anti-HCV NS2 and NS5 reactivities in relation to serotype of HCV, presence of HCV RNA and in acute HCV infection. *Clin. Diagn. Lab. Immun.* 1:290-294.
31. Zhang Z-X, **Chen M**, Wallhagen K, Tronjar J, Wahren B, Magnus LO, and Sällberg M. 1994. Molecular basis for antibody crossreactivity between hepatitis C virus core protein and the host derived protein GOR. *Clin. Exp. Immunol.* 96:403-409.
32. Yun Z, Reichard O, **Chen M**, Lundeberg J, Norkrantz G, Fryden A, Sönnerborg A, Weiland O. 1994. Serum hepatitis C virus RNA levels in chronic hepatitis C: Importance for outcome of interferon a-2b treatment. *Scand. J. Inf. Dis.* 26:263-270.